dual gip/glp-1 receptor agonist The Sustained Effects of a Agonist, NNC0090-2746, in Patients with Type 2 Diabetes Potential Use of GLP-1 and
Description
Diabetes 69 , 25892602 (2020)
Meanwhile, a study published in JAMA found that people taking tirzepatide drugs (e.g., Zepbound) have double the chance of developing NAION, a type of blindness
Mol Ther Nucleic Acids (2020) 23:61428
288 (2), R384R388 (2005)
This has led to pharmacies and companies selling their own versions of this medication
GLP-1 drugs are already changing how we treat obesity-related comorbidities
